SANGAMO THERAPEUTICS, INC - 8-K Filing
Sangamo Therapeutics completed $111M asset sale to PTC Therapeutics for ST-920 gene therapy candidate, with up to an additional $100M in contingent consideration (Items: 1.03 Bankruptcy or Receivership, 2.01 below is incorporated into this Item 1, 9.01 Financial Statements and Exhibits)
Tickers: $SGMO